NASDAQ:NTRP - Neurotrope Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $8.90 +0.34 (+3.97 %) (As of 09/20/2018 04:00 PM ET)Previous Close$8.56Today's Range$8.78 - $8.9052-Week Range$3.97 - $11.93Volume6,700 shsAverage Volume26,263 shsMarket Capitalization$70 millionP/E RatioN/ADividend YieldN/ABeta2.48 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Neurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardioprotection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a technology license and services agreement with Cognitive Research Enterprises, Inc. and its affiliate NRV II, LLC. The company was founded in 2012 and is based in New York, New York. Receive NTRP News and Ratings via Email Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:NTRP CUSIPN/A Webwww.neurotropebioscience.com Phone973-242-0005 Debt Debt-to-Equity RatioN/A Current Ratio11.90 Quick Ratio11.90 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$1.88 per share Price / Book4.73 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-12,610,000.00 Net MarginsN/A Return on Equity-74.23% Return on Assets-67.78% Miscellaneous Employees5 Outstanding Shares7,910,000Market Cap$70 million Neurotrope (NASDAQ:NTRP) Frequently Asked Questions What is Neurotrope's stock symbol? Neurotrope trades on the NASDAQ under the ticker symbol "NTRP." How were Neurotrope's earnings last quarter? Neurotrope Inc (NASDAQ:NTRP) released its quarterly earnings data on Friday, August, 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.12. View Neurotrope's Earnings History. When is Neurotrope's next earnings date? Neurotrope is scheduled to release their next quarterly earnings announcement on Friday, November, 9th 2018. View Earnings Estimates for Neurotrope. What price target have analysts set for NTRP? 2 analysts have issued 1 year price objectives for Neurotrope's shares. Their forecasts range from $15.00 to $16.00. On average, they expect Neurotrope's stock price to reach $15.50 in the next year. This suggests a possible upside of 74.2% from the stock's current price. View Analyst Price Targets for Neurotrope. What is the consensus analysts' recommendation for Neurotrope? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurotrope. What are Wall Street analysts saying about Neurotrope stock? Here are some recent quotes from research analysts about Neurotrope stock: 1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (8/17/2018) 2. Maxim Group analysts commented, "Neurotrope reported 2Q18 with a net loss of $2.1M and $11.8M in cash on the balance sheet." (8/13/2018) Who are some of Neurotrope's key competitors? Some companies that are related to Neurotrope include Corvus Pharmaceuticals (CRVS), Bellicum Pharmaceuticals (BLCM), Affimed (AFMD), MannKind (MNKD), Xenon Pharmaceuticals (XENE), Kala Pharmaceuticals (KALA), Aratana Therapeutics (PETX), Athersys (ATHX), Axovant Sciences (AXON), Melinta Therapeutics (MLNT), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Galectin Therapeutics (GALT), Menlo Therapeutics (MNLO), Ocular Therapeutix (OCUL) and Ardelyx (ARDX). Who are Neurotrope's key executives? Neurotrope's management team includes the folowing people: Dr. Charles S. Ryan, CEO & Director (Age 54)Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 76)Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 58)Mr. Jeffrey Benison, Director of Corp. CommunicationsMr. David R. Crockford, VP of Regulatory Affairs (Age 73) Has Neurotrope been receiving favorable news coverage? News articles about NTRP stock have been trending somewhat positive on Thursday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neurotrope earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned headlines about the company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. View Recent Headlines for Neurotrope. Who are Neurotrope's major shareholders? Neurotrope's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Tanaka Capital Management Inc. (2.51%), Neville Rodie & Shaw Inc. (1.38%), Ingalls & Snyder LLC (0.43%) and Renaissance Technologies LLC (0.37%). Company insiders that own Neurotrope stock include Bruce Bernstein, James Gottlieb and Kenneth J Gorelick. View Institutional Ownership Trends for Neurotrope. Which institutional investors are buying Neurotrope stock? NTRP stock was acquired by a variety of institutional investors in the last quarter, including Neville Rodie & Shaw Inc., Ingalls & Snyder LLC, Renaissance Technologies LLC and Tanaka Capital Management Inc.. Company insiders that have bought Neurotrope stock in the last two years include Bruce Bernstein and Kenneth J Gorelick. View Insider Buying and Selling for Neurotrope. How do I buy shares of Neurotrope? Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Neurotrope's stock price today? One share of NTRP stock can currently be purchased for approximately $8.90. How big of a company is Neurotrope? Neurotrope has a market capitalization of $70 million. Neurotrope employs 5 workers across the globe. How can I contact Neurotrope? Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected] MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 82 (Vote Outperform)Underperform Votes: 94 (Vote Underperform)Total Votes: 176MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: How can investors find ex-dividend dates?